# Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over

> **NCT06569823** · PHASE1,PHASE2 · RECRUITING · sponsor: **Dynavax Technologies Corporation** · enrollment: 764 (estimated)

## Conditions studied

- Shingles
- Herpes Zoster
- Vaccine-Preventable Diseases

## Interventions

- **BIOLOGICAL:** Z-1018
- **BIOLOGICAL:** Shingrix

## Key facts

- **NCT ID:** NCT06569823
- **Lead sponsor:** Dynavax Technologies Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-17
- **Primary completion:** 2027-11
- **Final completion:** 2031-11
- **Target enrollment:** 764 (ESTIMATED)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06569823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06569823, "Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06569823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*